NorthShore University HealthSystem added to COVID-19 digital biomarker study

June 17, 2021

physIQ announced that NorthShore University HealthSystem (NorthShore) has joined physIQ’s DeCODe study to develop an AI-based COVID-19 digital biomarker.

NorthShore will serve as an enrollment center and key partner in the Phase II validation stage of this study. The study is funded by the National Institutes of Health (NIH).

The DeCODe project is conducted in collaboration with the University of Illinois Hospital and Health Sciences System (UI Health). The objective of the study is to develop an early warning system potentially giving clinical teams more time to act on the warning signs of a person getting sick from COVID-19.  Rather than relying on periodic point measurements, such as temperature and pulse oximetry, continuous multi-parameter vital signs and physiological features will be monitored remotely in the patient’s home during activities of daily living.

To support the Phase II enrollment goal of 1,200 patients, NorthShore will enroll participants who are confirmed COVID-19 positive and recovering at home to evaluate the ability for the digital biomarker to detect and predict decompensation severity remote from the hospital.

This project has been funded in whole or in part with federal funds from the National Institutes of Health and Department of Health and Human Services.

physIQ has the release.

More COVID-19 coverage HERE.